Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  SHANGHAI STOCK EXCHANGE  >  Shanghai Pharmaceuticals Holding Co Ltd    601607   CNE000000C82

End-of-day quote. End-of-day quote  - 05/21
25.83 CNY   -0.39%
05/10SHANGHAI PHARMA : ·Reply Slip
PU
05/10SHANGHAI PHARMA : ·Proxy forms
PU
05/10SHANGHAI PHARMA : ·Circulars
PU
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Shanghai Pharmaceuticals : Advent, Shanghai Pharma have not approached Stada - sources

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/15/2017 | 08:54pm CEST
Logo of the pharmaceutical company Stada Arzneimittel AG is pictured at its headquarters in Bad Vilbel

FRANKFURT/LONDON (Reuters) - German drug company Stada Arzneimittel AG has not been approached by Advent International or Shanghai Pharmaceuticals Holding with a counter offer, two sources close to the matter told Reuters on Monday.

Rival buyout firms Bain and Cinven had offered to buy Stada in April, which seemed to end the contest to acquire the generic drug maker, but Bloomberg reported on Monday that Advent and Shanghai Pharmaceuticals are considering making an offer.

Bain and Cinven's offer of 65.28 euros per share and a dividend of 0.72 euros per Stada share was a surprisingly large increase on a previous bid and valued the company at about 5.3 billion euros (4.5 billion pounds).

Bloomberg reported that Advent and Shanghai Pharmaceuticals are discussing a potential bid of about 70 euros a share, citing people familiar with the matter.

However, Reuters' sources said a fresh bid from the duo is unlikely.

"Shanghai Pharmaceuticals is expected to struggle to secure the financing for a possible counterbid," the sources said. "They don’t have much time left to challenge Bain and Cinven."

Advent and Stada declined to comment and Reuters was unable to contact Shanghai Pharmaceuticals outside business hours.

(Additional reporting by Subrat Patnaik in Bengaluru; Editing by David Goodman)

By Alexander Hübner and Pamela Barbaglia

Stocks mentioned in the article
ChangeLast1st jan.
STADA ARZNEIMITTEL 0.24% 81.92 Delayed Quote.-7.15%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SHANGHAI PHARMACEUTICALS H
03:06pSHANGHAI PHARMACEUTICALS : SH Pharma to add 26.34% stake in Techpool Bio-pharma
AQ
05/10SHANGHAI PHARMACEUTICALS : ·Reply Slip
PU
05/10SHANGHAI PHARMACEUTICALS : ·Proxy forms
PU
05/10SHANGHAI PHARMACEUTICALS : ·Circulars
PU
05/10SHANGHAI PHARMACEUTICALS : ·Notice Of Annual General Meeting
PU
05/10SHANGHAI PHARMACEUTICALS : ·Notification Letter & Request Form(Registered..
PU
05/10SHANGHAI PHARMACEUTICALS : ·Notification Letter & Request Form(Non-regist..
PU
05/02SHANGHAI PHARMACEUTICALS : ·Monthly Return of Equity Issuer on Movements in Secu..
PU
04/20Generics group Alvogen puts Eastern European operations up for sale - sources
RE
04/17SHANGHAI PHARMACEUTICALS : ·Notice of Board Meeting
PU
More news
News from SeekingAlpha
2017Cardinal Health sells China business for $1.2B 
2017WEEK IN REVIEW : Vivace Details Its Capital Efficient Plan To Develop Novel Canc.. 
2015WEEK IN REVIEW : Hepalink Pharma Buys U.S.-Based CMO Cytovance 
2015WEEK IN REVIEW : Porton Fine Chemicals Buys Dongbang Pharma 
Financials ( CNY)
Sales 2018 162 B
EBIT 2018 5 763 M
Net income 2018 4 078 M
Debt 2018 7 260 M
Yield 2018 1,64%
P/E ratio 2018 18,24
P/E ratio 2019 16,28
EV / Sales 2018 0,46x
EV / Sales 2019 0,41x
Capitalization 67 356 M
Chart SHANGHAI PHARMACEUTICALS H
Duration : Period :
Shanghai Pharmaceuticals H Technical Analysis Chart | 601607 | CNE000000C82 | 4-Traders
Technical analysis trends SHANGHAI PHARMACEUTICALS H
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 26,1  CNY
Spread / Average Target 0,47%
EPS Revisions
Managers
NameTitle
Min Zuo President & Executive Director
Jun Zhou Chairman
You Li Xu Chairman-Supervisory Board
Bo Shen Chief Financial Officer, Director & Vice President
Xin Chen Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
SHANGHAI PHARMACEUTICALS HOLDING CO LTD7.19%10 543
SINOPHARM HOLDING CO LTD2.53%12 121
TSURUHA HOLDINGS INC.8.13%7 359
SUNDRUG CO LTD5.48%6 763
COSMOS PHARMACEUTICAL CORP3.70%4 403
SUGI HOLDINGS CO.,LTD.16.96%3 862